Sugammadex on Laparoscopic Bariatric Surgery

Launched by SHANXI BETHUNE HOSPITAL · Nov 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called sugammadex during laparoscopic bariatric surgery, which is a type of weight-loss surgery. Sugammadex helps reverse the effects of certain muscle relaxants used during surgery, making it easier for patients to wake up and breathe normally after the operation. This is particularly important for patients who are obese, as they may have breathing difficulties after surgery. The trial aims to see if sugammadex can improve recovery times and reduce complications related to breathing.

To be eligible for this trial, participants need to be between 18 and 50 years old, have a body mass index (BMI) of 40 or higher, and have a certain level of overall health as defined by the American Society of Anesthesiologists. However, those with specific muscle or breathing diseases, severe liver or kidney problems, or certain mental health issues will not be able to participate. If someone joins the trial, they can expect to receive either sugammadex or standard treatment during their surgery and will be monitored closely for their recovery. This research is important as it may lead to better outcomes for patients undergoing weight-loss surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-50 years
• • Body Mass Index (BMI) ≥ 40kg/m²
• • American Society of Anesthesiologists (ASA) grade I to III classification
• • NYHA cardiac function grade I - II
• Exclusion Criteria:
• • Patients with neuromuscular disease or respiratory system disease
• • Patients with severe abnormal liver and renal function
• • Perioperative use of drugs known to interact with rocuronium
• • Patients with unstable mental illness or refusal to participate